Crohn's Disease Drug Market to Experience Dynamic Growth of 73% By 2013
Posted on: Tuesday, 2 November 2004, 09:00 CST
WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the Crohn's disease drug market will experience dynamic growth of 73% by 2013. According to the new Pharmacor study entitled Crohn's Disease, the growth will be a direct result of the launch of novel biologic agents into the market.
"Several novel biologic agents in late-stage clinical development are expected to launch for the treatment of Crohn's disease in the next ten years," said Melissa G. Stolper, analyst at Decision Resources. "The launch of these emerging agents will expand the number of treatment options for patients with severe, refractory disease, and physicians will therefore be able to prescribe second- or third-line biologics for patients who fail to respond to a first-line biologic. The expanding percentage of patients who will be treated with biologics and the premium pricing of these new biologics will help drive composite 2013 sales for these emerging therapies to $843 milllion, a figure representing almost 50% of the overall Crohn's disease market in that year."
About Crohn's Disease
Crohn's disease is a chronic, relapsing/remitting inflammatory disease that predominantly affects the small and large intestines, including the rectum. In 2003, the diagnosed prevalent population in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) totaled more than 550,000.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com
Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Smart Payment Strategies Enable Growth in Home Health Care and Disease Management Markets for Remote Patient Monitoring, Finds Frost & Sullivan
- Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps
- The U.S. Remains Preferred Market for Launching New Products, According to Tufts Center for the Study of Drug Development
- Parkinson's Disease Latest Update: Market Upgrade Following Evidence of Disease Slowing With Azilect
- North American Home Health Care and Disease Management Markets for Remote Patient Monitoring
- CIGNA and Dartmouth-Hitchcock Launch ''Patient-Centered Medical Home'' Program to Provide Better Care Coordination
- The Target Marketing Group Launches Nation's First Retro Active Real Estate Relocation System
- Lumedx Launches Patient and Resource Scheduler Software
- Decision Resources Defines a Hypothetical Parkinson's Disease Drug That Would Earn 25% Patient Share
- ACS Chemical Biology - the New Interface of Chemistry and Biology - Launched
 |
 |
User Comments (0)
RSS Feeds